Live Breaking News & Updates on Yehs Vogt Koyanagi Harada

Autoimmune toxicities, while common following treatment with cancer immunotherapies, are not well-characterized in patients treated with BRAF/MEK inhibitors. Emerging data suggest that autoimmune effects may be linked with superior responses to both treatment modalities; however, there is little evidence describing mechanisms of immune-related toxicity for patients on BRAF/MEK inhibitors. Here we describe the experience of a 59-year-old HLA-A2, A29, B27-positive male patient with recurrent/metastatic melanoma. After progression on checkpoint inhibitor therapy, he was treated with dabrafenib/trametinib followed by encorafenib/binimetinib, which were well-tolerated. 18 months into BRAF/MEK inhibitor therapy, he developed a series of sudden-onset, severe toxicities including bilateral panuveitis, cytopenias, joint pain, skin rash, hypercalcemia and interstitial nephritis, which led to BRAF/MEKi cessation. At that time, the patient was found to have a complete response, which is ongoing at ....

Chiarion Sileni , Yehs Vogt Koyanagi Harada , Brafi Meki , Homet Moreno , Dummerr Development Of Encorafenib , Uveitis Study Group , Emory University , University Of South Carolina , V Foundation Translational Award , Eve Technologies Corporation Alberta , Institutional Review Board At Emory University , Cytokine Profile , Institutional Review Board , Medical University , South Carolina , Human Discovery , Eve Technologies Corporation , Reve Technologies , Side Effects , Targeted Therapy , Med Abstract , Crossref Full Text , Melanoma With , New Englj Med , Mutated Advanced , Curr Opin Oncol ,